ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï
‰ïˆõƒƒOƒCƒ“ ‘ã•\ˆ¥ŽA
‘‰ïEŠwpW‰ï
‹³ˆçŠˆ“®Ü
Šw‰ïŽ
’芼
Κ
—˜‰v‘Š”½
–ðˆõ\¬
Ž––±‹ÇˆÄ“à
‹lŽ{݈ꗗ
ŠÖ˜AƒŠƒ“ƒN

@ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‰ïŽ ƒIƒ“ƒ‰ƒCƒ“ƒWƒƒ[ƒiƒ‹

<< Šw‰ïނ֖߂é
<< ‘O‚̃y[ƒW‚Ö–ß‚é

y“ÁWz
—‘‘ƒ¬n”X–E«ŠïŒ`Žî‚ÌÄ”­‚ÉŠÖ‚·‚錟“¢


“¡–{@–ƒ—t, Œ´“c@”ü—R‹I, •½’r@C, “¡–{@W‹v, ‘å{‰ê@õ, “¡ˆä@’ms, –î–ì@“N, ãÈ@Žu˜Y
“Œ‹ž‘åŠwŽY‰È•wl‰È


Key wordsFMature cystic teratoma, Ovary, Recurrence, Risk factor

ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽ, 49(4) 679-682, 2012


ˆê”ÊŽÐ’c–@lŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽ––±‹Ç@§102-0083 “Œ‹ž“sç‘ã“c‹æ’¬4-7-7 ’¬ƒp[ƒNƒTƒCƒhƒrƒ‹402 Š”)MAƒRƒ“ƒxƒ“ƒVƒ‡ƒ“ƒRƒ“ƒTƒ‹ƒeƒBƒ“ƒO“à
TELF03-3288-0993@FAXF03-5275-1192@E-mailFkantorengo@jsog-k.jp
Copyright (C) ˆê”ÊŽÐ’c–@lŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï